Aerogen is a closed-circuit drug delivery system,2,3 which can help mitigate the release of fugitive aerosols during nebulisation†2, 4-6
The need to open a pressurised ventilator circuit to administer aerosolised medication is considered a potential risk factor for the release of fugitive aerosol.†2,7,8
In studies, the use of Aerogen vibrating mesh nebulisers was associated with lower fugitive aerosol emissions versus jet nebulisers during invasive mechanical ventilation (IMV),‡2 high-flow (HF),§6 and when self-ventilating (SV).﹟4,¶5
Aerogen, your solution to delivering inhaled medication to patients with COVID-19.
†Studies by Joyce et al and McGrath et al were performed in in-vitro models of mechanical ventilation and self-ventilation, respectively; studies by Harnois et al and Li et al were self-ventilation and high-flow studies, respectively, performed in healthy subjects
‡Defined as median (interquartile range) particulate number concentration during simulated drug refill in an in vitro model of invasive mechanical ventilation; between-group difference, 0/cm–3 (0.1–1.6) vs 710/cm-3 (265–1211); P=0.032
§Defined as fugitive aerosol concentrations versus baseline with Aerogen via Airvo 2 (high-flow) versus jet nebuliser with mouthpiece of facemask at particles of 1.0–3.0 µm (all P<0.05); study performed in healthy subjects.
¶Defined as fugitive aerosol concentrations with jet nebuliser vs Aerogen with a mask at particle sizes of 1.0–5 μm and with a mouthpiece at particle sizes of 0.5–3 μm (all P<0.05); study performed in healthy subjects
#Defined as mean aerosol concentrations at a distance of 0.8 m and 2.2 m over 30 minutes; in-vitro model of a self-ventilating adult
††When placed 15 cm from the Y-Piece in a heated setting; in-vitro model
‡‡Study performed in healthy subjects